UB Paderborn / Katalog / Suche / in CDI

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Blood, 2006-11, Vol.108 (10), p.3458-3464

2006

Volltextzugriff (PDF)

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

Oncology (Williston Park, N.Y.), 2010-03, Vol.24 (3 Suppl 2), p.22-29

2010

Volltextzugriff (PDF)

CLAMP and Zelda function together to promote Drosophila zygotic genome activation

eLife, 2021-08, Vol.10

2021

Volltextzugriff (PDF)

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Blood, 2002-11, Vol.100 (9), p.3063-3067

2002

Volltextzugriff (PDF)

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of clinical oncology, 2009-12, Vol.27 (34), p.5713-5719

2009

Volltextzugriff (PDF)

A Qualitative Metasynthesis of Consultation Process Research: What We Know and Where to Go

Journal of educational and psychological consultation, 2017-01, Vol.27 (1), p.13-51

2017

Volltextzugriff (PDF)

Clean energy technology pathways from research to commercialization: Policy and practice case studies

Frontiers in energy research, 2022-11, Vol.10

2022

Volltextzugriff (PDF)

Transdisciplinary translational science and the case of preterm birth

Journal of perinatology, 2013-04, Vol.33 (4), p.251-258

2013

Volltextzugriff (PDF)

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

European journal of haematology, 2012-05, Vol.88 (5), p.446-449

2012

Volltextzugriff (PDF)

Glycemic and Blood Pressure Responses to Acute Doses of Rebaudioside A, a Steviol Glycoside, in Subjects with Normal Glucose Tolerance or Type 2 Diabetes Mellitus

The FASEB journal, 2009-04, Vol.23 (S1)

2009

Volltextzugriff (PDF)

Electronic Communication and Changing Organizational Forms

Organization science (Providence, R.I.), 1995-07, Vol.6 (4), p.337-349

1995

Volltextzugriff (PDF)

Linkages in the Rural Continuum: The Balanced Budget Act and Beyond

The Gerontologist, 2003-04, Vol.43 (2), p.151-157

2003

Volltextzugriff (PDF)

Agricultural impacts of and responses to climate change in the Missouri-Iowa-Nebraska-Kansas (Mink) region

Climatic change, 1993-06, Vol.24 (1-2), p.23-23

1993

Volltextzugriff (PDF)

Pomalidomide for the treatment of relapsed and refractory multiple myeloma

Expert opinion on orphan drugs, 2014-10, Vol.2 (10), p.1089-1108

2014

Volltextzugriff (PDF)

Pulsed-power driven inertial confinement fusion development at Sandia National Laboratories

IEEE transactions on plasma science, 2012-05, Vol.40 (12)

2012

Volltextzugriff (PDF)

Contextual clustering for configuring collaborative conservation of watersheds in the Mid-Atlantic Highlands

Environmental and ecological statistics, 2006-12, Vol.13 (4), p.391-407

2006

Volltextzugriff (PDF)

The potential impacts of climate change and variability on forests and forestry in the Mid-Atlantic Region

Climate research, 2000-05, Vol.14 (3), p.195-206

2000

Volltextzugriff (PDF)

Electronic Medical Records and Mortality in Trauma Patients

The Journal of trauma, injury, infection, and critical care, 2009-09, Vol.67 (3), p.634-636

2009

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Commentary

CLAMP and Zelda function together to promote Drosophila zygotic genome activation

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

A Qualitative Metasynthesis of Consultation Process Research: What We Know and Where to Go

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Clean energy technology pathways from research to commercialization: Policy and practice case studies

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Transdisciplinary translational science and the case of preterm birth

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

Glycemic and Blood Pressure Responses to Acute Doses of Rebaudioside A, a Steviol Glycoside, in Subjects with Normal Glucose Tolerance or Type 2 Diabetes Mellitus

Electronic Communication and Changing Organizational Forms

Linkages in the Rural Continuum: The Balanced Budget Act and Beyond

Agricultural impacts of and responses to climate change in the Missouri-Iowa-Nebraska-Kansas (Mink) region

Pomalidomide for the treatment of relapsed and refractory multiple myeloma

Pulsed-power driven inertial confinement fusion development at Sandia National Laboratories

Contextual clustering for configuring collaborative conservation of watersheds in the Mid-Atlantic Highlands

The potential impacts of climate change and variability on forests and forestry in the Mid-Atlantic Region

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM)

Phase I Clinical Trial of Oral Administration of the Histone Deacetylase (HDAC) Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Relapsed/Refractory Multiple Myeloma (MM)

Electronic Medical Records and Mortality in Trauma Patients

Suchergebnisse filtern